Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Shares of Mylan extended losses Friday after a lawmaker said the Centers for Medicare and Medicaid Services found that Mylan misclassified the lifesaving EpiPen device.
CMS found that Mylan had misclassified the EpiPen as a "non-innovator multiple source drug," or a generic drug.
The error resulted in the overpayment for the drug by the government on a federal and state level through the Medicaid Drug Rebate Program.
For drugs classified as generic, companies pay a 13 percent rebate to Medicaid, compared to the 23 percent rebate for branded drugs.
"The Minnesota Department of Human Services has estimated that this misclassification will cost our state more than $4 million in overpayment this year alone," wrote Senator Klobuchar in a letter to the Centers for Medicare & Medicaid Services (CMS).
Klobuchar demanded a nationwide investigation by CMS.